Steris stock holds steady as valuation and earnings support long-term growth
Published on 08/18/2026 at 12:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Steris plc (ISIN IE00BFY8C754) stock continues to trade at a substantial valuation, reflecting the company’s steady earnings profile and market position in healthcare sterilization and infection prevention as of August 18, 2026.
Recent market data show Steris stock quoted in the low-$230s in intraday trading on August 18, 2026, with a prior closing level of $229.81 on August 17, 2026 and a market capitalization reported at $22.41 billion, underlining the company’s large-cap status in the medical technology space.
That same data snapshot indicates Steris shares closed at $229.81 on August 17, 2026, down 1.49% for that session, while the broader valuation picture includes a trailing price-to-earnings multiple of 28.85 based on trailing twelve-month earnings per share of $7.97, suggesting that investors are paying more than $28 for each dollar of recent earnings.
Market valuation and share performance
According to one recent market overview of the New York Stock Exchange listing for Steris, the company’s ticker symbol is STE and the most recent official close recorded in that overview was $229.81 on August 17, 2026, with the same source stating the current share quote at $229.81 within its data set, indicating a relatively stable price over that short period.
The same overview places Steris’s market capitalization at $22.41 billion as of that reporting, reinforcing its classification among the larger healthcare equipment and services companies, and providing context for the liquidity and institutional interest in the shares.
For investors assessing valuation, the trailing twelve-month earnings per share of $7.97 and a trailing price-to-earnings ratio of 28.85 as reported in that market data imply that Steris trades at a premium relative to many broad-market averages, with the ratio quantifying the market’s willingness to pay $28.85 for each $1.00 of EPS generated over the past year.
Analyst expectations and comparison
The same market-data summary also highlights that, based on compiled analyst views, Steris shares carry an overall rating categorized as Buy, accompanied by a consensus price target of $265.99, which stands notably above the recent closing price of $229.81 and implies upside in the range of roughly $36 per share if those targets were realized.
Putting that implied upside into perspective, the difference between the $265.99 target and the $229.81 latest close is $36.18 per share, which corresponds to a potential gain in the order of 15.7% on the latest close if the stock were to reach the consensus target, underscoring that analysts see room for further appreciation based on their models.
The valuation context is further enriched by the earnings metric: with EPS of $7.97 over the trailing twelve months, the consensus price target of $265.99 would represent a forward-looking multiple of about 33.36 times that EPS, a higher ratio than the current 28.85 and one that reflects expectations for continued earnings growth or a willingness to accept a richer valuation multiple.
Business model and key product focus
Steris plc operates a diversified portfolio focused on infection prevention, decontamination, and sterilization solutions for hospitals, surgical centers, and other healthcare providers, as well as industrial and research settings, positioning the company across several critical nodes of patient safety and equipment hygiene.
The company’s offerings typically include sterilization systems, washers, disinfectants, and related consumables that are used to ensure that surgical instruments, endoscopes, and other reusable medical devices are safe for use and comply with stringent regulatory and clinical standards.
In addition, Steris supplies equipment and services associated with operating room infrastructure, such as surgical tables, lighting, and integrated systems, which ties the business closely to overall hospital capital spending cycles and the broader trend of investing in operating suite modernization and infection control.
Representative Steris product in infection prevention
A representative example of Steris’s product range is its automated washing and disinfection systems for surgical instruments and endoscopes, which are designed to standardize the cleaning process and minimize human error in critical stages of instrument reprocessing.
These systems typically combine mechanical washing actions, controlled temperature cycles, and dosing of validated detergents and disinfectants, ensuring that each instrument batch goes through a reproducible and documented process before being sterilized or returned to clinical use.
For hospitals and surgical centers, such equipment reduces turnaround time between procedures, supports compliance with infection-prevention standards, and helps lower the risk of contamination that could lead to healthcare-associated infections, making the reliability and performance of Steris’s systems central to its value proposition.
Steris stock and closing market context
As of the close on August 17, 2026, Steris stock was recorded at $229.81 on its New York Stock Exchange listing, with the shares trading in USD and carrying a market capitalization of $22.41 billion at that valuation level.
In the broader context of healthcare and medical technology equities, that price level and market cap suggest Steris is a significant player within its niche, and the combination of trailing EPS of $7.97, a P/E ratio of 28.85, and a consensus price target of $265.99 offers investors a quantified framework for evaluating both the current valuation and the potential for future share price moves within the sector.
Fact box
Company: Steris plc
ISIN: IE00BFY8C754
Ticker: STE
Exchange: New York Stock Exchange (primary listing, USD)
Price (as of August 17, 2026, 4:00 p.m. ET): $229.81 USD
Market cap: $22.41 billion (as of August 17, 2026)
Sector / Industry: Healthcare equipment and services, medical technology
Index membership: Included in major healthcare and broad-market benchmarks where applicable
